Patient-reported outcomes—selfassessments of patient health status—are central to COVID-19 response, recovery, and resilience. Symptom reporting using patientreported outcomes can facilitate diagnosis of the disease, identify those who require tests, and initiate track and trace procedures. Additionally, remote monitoring of symptoms with the use of electronic patientreported outcomes can help identify those with severe COVID-19 who are in need of urgent care and those with mild-to-moderate symptoms that can be managed at home. The use of electronic patient-reported outcome systems is especially important because rapid deterioration can occur in patients with mild symptoms. Remote monitoring could also facilitate the triage of patients with chronic conditions ensuring that inperson hospital appointments are reserved for those with potentially life-threatening issues. Individuals with lower risk could be supported virtually and monitored for signs of deterioration. This approach can relieve the strain on health-care systems and prevent unnecessary exposures to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 We are just beginning to understand the long-term effects of SARS-CoV-2 infection. The symptoms have returned in some patients a few months postrecovery, and others have developed serious conditions such as Kawasakilike disease. Patient-reported outcomes could be used for long-term follow-up to assess the effect of the disease on a patient’s quality of life and to alert physicians to the development of potentially life-threatening complications.

Work has begun in earnest to develop effective drugs and vaccines to stem the spread of SARS-CoV-2 and prevent future outbreaks. Nevertheless, some unknowns such as potency, side-effects, and adverse events might only come to light during human trials. The first in-human COVID-19 vaccine trial used diary cards completed by trial participants to monitor adverse events. 2 Although it was encouraging that participant views were sought, we recommend the use of validated patient-reported outcome instruments such as the patient-reported outcomes version of the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE). 3 Use of this instrument in COVID-19 trials could complement the clinical CTCAE and facilitate cross-trial comparisons of results. Evidence suggests that